Cargando…

Interleukin 35: protective role and mechanism in type 1 diabetes

Interleukin 35 (IL-35), a cytokine secreted by regulatory T (Treg) cells from the differentiation of conventional CD4(+) T cells, is a member of the IL-12 family. The IL-12 family of cytokines exhibits an anti-inflammatory property. IL-35 has recently been shown to influence the immune modulation in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Si-Ming, Liang, Jun, Xia, Ji-Ping, Li, Li, Zheng, Li, Wang, Ya-Lan, Li, Yan-Hong, Li, Yan, Lu, Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2023
Materias:	Review Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189575/ https://www.ncbi.nlm.nih.gov/pubmed/37206590 http://dx.doi.org/10.5114/ceji.2023.125043

Ejemplares similares

Elevated levels of interleukin‐35 and interleukin‐37 in adult patients with obstructive sleep apnea
por: Chen, Bi, et al.
Publicado: (2021)

Cytokines in type 1 diabetes: mechanisms of action and immunotherapeutic targets
por: Lu, Jingli, et al.
Publicado: (2020)

Interleukin 35 regulates interleukin 17 expression and T helper 17 in patients with proliferative diabetic retinopathy
por: Yan, Ai, et al.
Publicado: (2022)

Interleukin-35 Is Involved in Angiogenesis/Bone Remodeling Coupling Through T Helper 17/Interleukin-17 Axis
por: Zhang, Hui, et al.
Publicado: (2021)

Pathogen effector AvrSr35 triggers Sr35 resistosome assembly via a direct recognition mechanism
por: Zhao, Yan-Bo, et al.
Publicado: (2022)

Interleukin-35 as an Emerging Player in Tumor Microenvironment
por: Xue, Wenhua, et al.
Publicado: (2019)

Pathogenesis and Function of Interleukin-35 in Rheumatoid Arthritis
por: Xin, Pan Lin, et al.
Publicado: (2021)

Interleukin-35 promotes progression of prostate cancer and inhibits anti-tumour immunity
por: Zhu, Jialin, et al.
Publicado: (2020)

Different expression levels of interleukin-35 in asthma phenotypes
por: Li, Wei, et al.
Publicado: (2020)

Interleukin-35 exhibits protective effects in a rat model of hypoxic-ischemic encephalopathy through the inhibition of microglia-mediated inflammation
por: Liu, Guangliang, et al.
Publicado: (2022)

Interleukin-35 Attenuates D-Galactosamine/Lipopolysaccharide-Induced Liver Injury via Enhancing Interleukin-10 Production in Kupffer Cells
por: Zheng, Xing-Feng, et al.
Publicado: (2018)

Association between interleukin‐19 and angiopoietin‐2 with vascular complications in type 2 diabetes
por: Li, Li, et al.
Publicado: (2016)

The Role, Involvement and Function(s) of Interleukin-35 and Interleukin-37 in Disease Pathogenesis
por: Omenesa Bello, Ramatu, et al.
Publicado: (2018)

Interleukin-35 is associated with the tumorigenesis and progression of prostate cancer
por: Zhu, Jialin, et al.
Publicado: (2019)

Pretreatment with interleukin 35-engineered mesenchymal stem cells protected against lipopolysaccharide-induced acute lung injury via pulmonary inflammation suppression
por: Zhang, Xiaoning, et al.
Publicado: (2020)

A Review of Clinical and Preclinical Studies on Therapeutic Strategies Using Interleukin-12 in Cancer Therapy and the Protective Role of Interleukin-12 in Hematological Recovery in Chemoradiotherapy
por: Li, Ping, et al.
Publicado: (2020)

Lower serum interleukin‐22 and interleukin‐35 levels are associated with disease status in neuromyelitis optica spectrum disorders
por: Yang, Hong, et al.
Publicado: (2019)

Overexpression of interleukin-35 associates with hepatocellular carcinoma aggressiveness and recurrence after curative resection
por: Fu, Yi-Peng, et al.
Publicado: (2016)

Knockdown of Expression of Cdk5 or p35 (a Cdk5 Activator) Results in Podocyte Apoptosis
por: Zheng, Ya-Li, et al.
Publicado: (2016)

Interleukin-35 administration counteracts established murine type 1 diabetes – possible involvement of regulatory T cells
por: Singh, Kailash, et al.
Publicado: (2015)

Serum levels of interleukin-23 and 35 in patients with and without type 2 diabetes mellitus and chronic periodontitis
por: Maboudi, Avideh, et al.
Publicado: (2019)

Interleukin 35 induced Th2 and Tregs bias under normal conditions in mice
por: Zhang, Xiaoning, et al.
Publicado: (2018)

Interleukin-35 Prevents the Elevation of the M1/M2 Ratio of Macrophages in Experimental Type 1 Diabetes
por: Luo, Zhengkang, et al.
Publicado: (2022)

The association between interleukin-19 concentration and diabetic nephropathy
por: Li, Li, et al.
Publicado: (2017)

Prevention of Autoimmune Diabetes by Ectopic Pancreatic β-Cell Expression of Interleukin-35
por: Bettini, Maria, et al.
Publicado: (2012)

Interleukin-35 sensitizes monocytes from patients with asthma to glucocorticoid therapy by regulating p38 MAPK
por: Qian, Lei, et al.
Publicado: (2020)

Protective Effects of Interleukin-37 Expression against Acetaminophen-Induced Hepatotoxicity in Mice
por: Xu, Zhiwei, et al.
Publicado: (2022)

Interleukin 39: a new member of interleukin 12 family
por: LU, ZHIYU, et al.
Publicado: (2020)

Immunomodulatory cytokine interleukin-35 and immune thrombocytopaenia
por: Zhu, Jing-Jing, et al.
Publicado: (2020)

Interleukin-35 in autoimmune dermatoses: Current concepts
por: Xie, Yuming, et al.
Publicado: (2022)

Interleukin-35 promotes Breg expansion and interleukin-10 production in CD19(+) B cells in patients with ankylosing spondylitis
por: Zhang, Yu, et al.
Publicado: (2022)

Type 2 diabetes epidemic in East Asia: a 35–year systematic trend analysis
por: Yuan, Huiping, et al.
Publicado: (2017)

Inducible nitric oxide synthase-expressing myeloid-derived suppressor cells regulated by interleukin 35 contribute to the pathogenesis of psoriasis
por: Zhang, Junfeng, et al.
Publicado: (2023)

Analysis for interaction between interleukin-35 genes polymorphisms and risk factors on susceptibility to coronary heart disease in the Chinese Han population
por: Li, Hu, et al.
Publicado: (2021)

Systems pharmacology approach reveals protective mechanisms of Jian-Pi Qing-Chang decoction on ulcerative colitis
por: Chen, You-Lan, et al.
Publicado: (2019)

Investigation of the Potential Phlorotannins and Mechanism of Six Brown Algae in Treating Type II Diabetes Mellitus Based on Biological Activity, UPLC-QE-MS/MS, and Network Pharmacology
por: Chen, Jialiang, et al.
Publicado: (2023)

Correction: Colon cancer-induced interleukin-35 inhibits betacatenin- mediated pro-oncogenic activity
por: Jiang, Yueqiang, et al.
Publicado: (2018)

Colon cancer-induced interleukin-35 inhibits beta-catenin-mediated pro-oncogenic activity
por: Jiang, QiangYue, et al.
Publicado: (2017)

Neutralization of Interleukin-16 Protects Nonobese Diabetic Mice From Autoimmune Type 1 Diabetes by a CCL4-Dependent Mechanism
por: Meagher, Craig, et al.
Publicado: (2010)

Effect of Inhaled Budesonide on Interleukin-4 and Interleukin-6 in Exhaled Breath Condensate of Asthmatic Patients
por: Chi, Chun-Hua, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_cl56nr2s5lth6617880m9gpq2g